Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Juli 2026 07:13 ET | Quelle: Jupiter Neurosciences, Inc.

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July...
21. Juli 2026 07:00 ET | Quelle: PharmAla Biotech

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

PharmAla signs definitive agreement with Jupiter Neurosciences to out-license their patented ALA-002 molecule, securing up-front and development payments.
20. Mai 2026 08:15 ET | Quelle: PharmAla Biotech

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
20. Mai 2026 07:38 ET | Quelle: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May ...